Logotype for Xero Limited

Xero (XRO) H1 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Xero Limited

H1 2027 earnings summary

12 Nov, 2026

Executive summary

  • H1 FY27 revenue was NZ$1,745.3m, up 46% reported and 27% pro forma; adjusted EBITDA reached NZ$361.6m and pro forma free cash flow rose 32%.

  • Customer additions, higher ARPC, payments growth and product adoption supported performance; FY27 revenue and adjusted EBITDA guidance increased.

  • FY27 pro forma Rule of 40 is expected at ~40%, a year ahead of the prior aspiration; FY28 revenue aspiration rose above NZ$4.6bn, excluding synergies.

  • An on-market buy-back of up to A$1bn was approved; Melio-related margin and profit pressure continued.

Financial highlights

  • Operating revenue was NZ$1,745.3m, up 46% reported and 41% in constant currency; pro forma growth was 27%, or 22% in constant currency.

  • Adjusted EBITDA was NZ$361.6m, up 3% reported and 23% pro forma; reported EBITDA was NZ$347.5m and EBIT was NZ$109.9m.

  • Pro forma free cash flow rose 32% to NZ$238.1m; reported free cash flow fell 26% to NZ$238.1m, partly reflecting Melio inclusion.

  • Pro forma gross profit increased 22% to NZ$1,327m; pro forma gross margin declined 3.1 percentage points to 76.0%, mainly from Melio payment mix.

  • Net profit fell 86% to NZ$18.5m, reflecting Melio’s incorporation and the non-recurrence of prior-year foreign-exchange gains on term deposits.

Outlook and guidance

  • FY27 revenue guidance increased to NZ$3.77bn–NZ$3.83bn from NZ$3.62bn–NZ$3.73bn; pro forma constant-currency growth is expected at 24%–27%.

  • FY27 adjusted EBITDA guidance is NZ$880m–NZ$920m, raised from a prior NZ$860m–NZ$920m range; H2 is expected to carry higher-than-historical weighting.

  • FY27 pro forma Rule of 40 is expected at ~40%; FY28 revenue aspiration is above NZ$4.6bn excluding revenue synergies, with Rule of 40 above 40%.

  • Melio is expected to reach adjusted EBITDA breakeven on a run-rate basis in H2 FY28; NZ$70m of revenue synergies are expected in FY28.

  • FY27 D&A is estimated at NZ$475m; product capitalisation rates are expected within the long-term 40%–45% range.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Xero